GlaxoSmithKline (GB:GSK) has released an update.
GlaxoSmithKline (GSK) has announced encouraging results from a phase II trial of its mRNA seasonal influenza vaccine, which showed positive immune responses in both younger and older adults compared to current vaccines. The trial’s success paves the way for phase III clinical trials, marking significant progress in GSK’s mRNA vaccine development. The company aims to offer a new best-in-class vaccine, bolstering its capabilities through strategic partnerships and investments in AI and manufacturing technologies.
For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.
